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Protein therapy refers to the direct delivery of therapeutic proteins to cells and tissues 
with the goal of ameliorating or modifying a disease process. Current techniques for 
delivering proteins across cell membranes include taking advantage of receptor-
mediated endocytosis or using protein transduction domains that penetrate directly into 
cells. The most commonly used protein transduction domains are small cell-penetrating 
peptides derived from such proteins as the HIV-1 Tat protein. A novel protein-
transduction domain developed as the single-chain fragment (Fv) of a murine anti-DNA 
autoantibody, mAb 3E10, has recently been developed and used to deliver biologically 
active proteins to living cells in vitro. This review will provide a brief overview of the 
development of the Fv fragment and provide a summary of recent studies using Fv to 
deliver therapeutic peptides and proteins (such as a C-terminal p53 peptide, C-terminal 
p53 antibody fragment, full-length p53, and microdystrophin) to cells. 
KEYWORDS: antibody, antibodies, autoantibody, autoantibodies, single-chain Fv, protein 
therapy, gene therapy, p53, dystrophin, cancer, muscular dystrophy, protein transduction, ptd, 
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INTRODUCTION 
Development of a means to restore missing proteins to diseased cells consistently and efficiently remains 
a prominent goal in molecular medicine. While gene therapy has the potential to accomplish this task, 
considerable obstacles must be overcome before it becomes clinically applicable. Alternatives to gene 
therapy need to be considered in the interim. One such alternative, protein therapy, comprises the direct 
delivery of missing proteins to cells. Protein therapy circumvents the need for transfer of genetic material 
into cells, thereby avoiding many of the problems and dangers associated with gene therapy.  
As protein transduction techniques improve, greater interest in protein therapy has driven increasing 
efforts toward discovering and refining protein delivery vehicles. A significant amount of research has 
focused on cell-penetrating peptides (CPPs), which are short, basic peptides that penetrate into living 
cells[1]. The most frequently studied CPPs include HIV-1 Tat peptide, HSV VP-22 peptide, penetratin, 
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and simple polyarginine peptides. Fusion of CPPs to other proteins confers transducibility to the fusion 
protein and has been used to deliver a variety of proteins to living cells both in vitro and in 
vivo[2,3,4,5,6]. While these peptides are of obvious interest and hold great potential in protein therapy, 
their use in the treatment of human disease may be limited by documented proinflammatory and toxic 
characteristics[7,8,9,10].  
ANTIBODIES AS INTRACELLULAR DELIVERY VEHICLES 
Receptor-mediated endocytosis of antibody-conjugated molecules has been extensively studied and 
reviewed[11]. The use of antibodies and antibody fragments as protein transduction domains, however, is 
an emerging field. Living cells can be penetrated by certain autoantibodies, including some that bind 
DNA[12,13]. The penetration of living cells by these anti-DNA autoantibodies led researchers to 
investigate the potential of autoantibody protein transduction domains as intracellular protein delivery 
vehicles. The noninflammatory and nonimmunogenic nature of antibodies coupled with their potential to 
induce tolerance to themselves and to a protein cargo make antibodies highly attractive candidates for 
development into intracellular delivery vehicles[14,15]. While many autoantibodies have associated 
cytotoxicities, some appear to be benign. An anti-DNA autoantibody produced by MRL/mpj/lpr mice 
with lupus nephritis, mAb 3E10, has recently been developed into a novel intracellular delivery vehicle 
and has been used to deliver a multitude of potentially therapeutic proteins into living cells[16]. This 
review will provide a brief survey of recent progress that has been made in using mAb 3E10 to deliver 
therapeutic proteins to living cells.  
mAb 3E10 
In 2000, Weisbart et al. demonstrated a novel role for mAb 3E10 in delivering functional proteins to 
living cells. mAb 3E10 was covalently linked to bovine catalase enzyme, and the conjugate protein was 
analyzed both for ability to penetrate into living cells in vitro and to protect primary rat cortical neurons 
against oxidative damage. Neurons incubated with the mAb 3E10-catalase conjugate showed penetration 
of the conjugate into both the nuclei and cytoplasm of the neurons, while neurons incubated with free 
catalase showed no uptake of catalase into the cytoplasm or nuclei. Additionally, neurons transduced by 
the mAb 3E10-catalase conjugate were resistant to H2O2 toxicity compared to neurons incubated with 
unconjugated catalase[17]. The results demonstrated that mAb 3E10 was not only capable of penetrating 
into living cells itself, but also of carrying another protein into cells. Furthermore, the neuroprotection 
afforded by the mAb 3E10-catalase conjugate protein established the ability of mAb 3E10 to deliver 
functional, biologically active proteins to living cells.  
Additional efforts focused on optimizing the transduction efficiency of the mAb 3E10 antibody and 
identifying the minimal portions of the antibody required for cellular penetration. First, a single change of 
an aspartic acid to an asparagine residue at position 31 in CDR 1 of the VH region of the antibody greatly 
increased its transduction efficiency as indicated by greater percentages of cells transduced at smaller 
concentrations of the antibody[16]. Second, smaller Fab and single-chain fragments of the mutant mAb 
3E10 antibody were found to penetrate into living cells equally as well as the full-length antibody. 
Impressively, Fab fragments delivered alkaline phosphatase-conjugated goat antibodies, estimated at 305 
kDa in size, into the nuclei of living cells[18]. While the full-length mAb 3E10 and Fab fragments of 
mAb 3E10 have been established as viable intracellular delivery vehicles for protein transduction, the 
single-chain fragment has been the primary focus of recent studies. 
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THE FV FRAGMENT OF MAB 3E10 
The single-chain fragment of mAb 3E10, Fv, consists of the variable region of both the light and heavy 
chains of mAb 3E10 cross-linked by a short (GGGGS)3 linking sequence (Fig. 1). Fv penetrates living 
cells and localizes to the nucleus as well as the full-length antibody and the Fab fragments. Fv-fusion 
proteins also penetrate into cells and nuclei. For example, an Fv-GFP fusion protein was the first Fv-
fusion protein studied, and it entered cells and localized to nuclei[18]. The smaller size of the Fv fragment 
when compared to the mAb 3E10 antibody or its Fab fragments makes Fv most attractive in attempting to 
deliver therapeutic proteins to cells. Toxicity of the Fv fragment has been excluded by generation of CHO 
cell lines stably expressing Fv cDNA. These CHO cells were subjected to Fv in two ways: they 
synthesized and secreted the Fv fragment and were then transduced by the secreted Fv. The cells 
proliferated at a normal rate and excluded trypan blue comparably to other nontransfected CHO cells[18]. 
After the identification of the Fv fragment as a small component of the antibody capable of transduction 
and with its demonstrated absence of cytotoxicity, several studies successfully used the Fv fragment to 
deliver therapeutic peptides and proteins to cells. 
 
FIGURE 1. The single-chain Fv fragment of mAb 3E10. A transducible single-chain Fv 
fragment of mAb 3E10 was generated by cross-linking the variable regions of the 
antibody’s light (VL) and heavy (VH) chains. A myc tag was added to aid in detection of 
the Fv fragment and a histidine tag was added for purification of the Fv fragment and Fv-
fusion proteins. (L = [GGGGS]3 linking sequence, CH = constant region of mAb 3E10 
heavy chain, CL = constant region of mAb 3E10 light chain.)  
FV AS A MEANS TO RESTORE P53 FUNCTION TO CANCER CELLS 
Of the cancers afflicting humans worldwide, approximately 50% are related to mutations or defects in the 
p53 tumor suppressor protein, and a significant amount of effort has been focused into restoring 
functional p53 to cancer cells[19,20,21]. At least part of p53 activity depends on its ability to activate 
transcription of specific target genes, and given Fv’s predilection for localizing to cell nuclei, Fv is 
uniquely positioned to deliver factors into the nucleus of cancer cells with the goal of modulating p53 
activity. Several reported studies have established that C-terminal peptides of p53 and antibodies that bind 
the C-terminus of p53 activate transcription-defective mutant p53[22,23]. However, these peptides and 
antibodies lack an efficient means of delivery into cells. Fv was examined for its ability to deliver such C-
terminal peptides or antibodies to cancer cells in the hopes of activating mutant p53 and killing cancer 
cells. 
A fusion protein consisting of the Fv fragment and a 30-mer C-terminal p53 peptide known to 
activate mutant p53 was produced as a secreted protein in Cos-7 cells. SW480 human colon 
adenocarcinoma cells were selected for testing the Fv-peptide fusion protein, as these cells are cancerous 
due to a mutation in p53 that renders it transcriptionally inactive. The Fv-peptide fusion protein 
penetrated into the SW480 cells and localized to nuclei as expected, but induced only modest killing of 
the cancer cells (approximately 10% of cells). In an assay to detect transcriptional activity of p53, SW480 
cells were transfected with a CAT reporter plasmid. As expected, control, nontransduced SW480 cells 
showed no baseline p53 trancriptional activation. Interestingly, SW480 cells transduced by the Fv-peptide 
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fusion protein also failed to report any detectable level of p53 transcriptional activity[24]. The failure of 
the Fv-peptide fusion protein to induce any detectable level of activation of p53 likely accounts for the 
low percentage of cells killed, and may indicate that the comparatively large Fv fragment interfered with 
the ability of the peptide to interact with p53. 
Next, a bispecific antibody composed of the Fv fragment and a single-chain fragment of an anti-p53 
antibody, mAb PAb421, was constructed and expressed as a secreted protein in Pichia pastoris. Similar 
to the C-terminal peptides of p53, mAb PAb421 binds the C-terminus of p53 and restores transcriptional 
activity to mutant p53[25,26]. Two cell lines, SW480 and Cos-7 African green monkey kidney cells, were 
used to test the bispecific antibody. SW480 cells, with their mutant p53, would be expected to be 
sensitive to activation of p53 by mAb PAb421. Cos-7 cells, which express the SV40 large T antigen that 
prevents the mAb PAb421 antibody from binding the C-terminus of p53, should be resistant to activation 
of p53 by the bispecific antibody. The bispecific antibody penetrated into both cell types and, as 
predicted, induced cell death in the SW480 cells but spared the Cos-7 cells. While the bispecific antibody 
appeared to specifically activate mutant p53 in the SW480 cells and induce cell killing, the relative 
amount of cell death was only 36%. The modest level of killing by the bispecific antibody was attributed 
to low levels of mutant p53 in the SW480 cells. Transfection of a plasmid to induce increased expression 
of p53 into cells prior to treatment with the bispecific antibody increased the percentage of cells killed to 
approximately 55%[27]. 
FV DELIVERS FUNCTIONAL, FULL-LENGTH P53 TO CANCER CELLS 
Given the results achieved with both the Fv-peptide fusion protein and the bispecific antibody, attention 
shifted from using Fv as a means to activate mutant p53 to using Fv to deliver full-length, functional wild 
type p53 protein to cancer cells. An Fv-p53 fusion protein was generated and expressed as an intracellular 
protein in P. pastoris. Several cell lines were used to test the efficacy of Fv-p53, including wild type 
primary cells (primary astrocytes) and cells cancerous due to absence of p53 (Saos-2 human osteosarcoma 
and Skov-3 human ovarian carcinoma cells), mutation in p53 (HT-29 human colon adenocarcinoma 
cells), nuclear exclusion of p53 (PC-12 human pheochromocytoma cells), overexpression of the negative 
regulatory protein MDM2 (MC-7 human breast cancer cells), and expression of T antigen (Cos-7 cells). 
Fv-p53 successfully penetrated into all of the cells examined and localized in both the nuclei and 
throughout the cytoplasm. Excitingly, Fv-p53 had a profound and specific effect on the cells, killing 
approximately 90% of the Saos-2, Skov-3, PC-12, and MC-7 cells and 45% of the HT-29 cells, while 
sparing the primary astrocytes and Cos-7 cells[28]. Whether Fv-p53 induces apoptosis in cancer cells 
through transcription-dependent or transcription-independent pathways is presently under investigation. 
Regardless of the mechanism, Fv-p53 is effective in penetrating and killing a vast array of cancer cell 
types, while at the same time sparing normal control cells, indicating great clinical potential in the 
treatment of cancer. The true clinical potential of Fv-p53 is currently being evaluated in in vivo 
experiments.  
FV DELIVERS MICRODYSTROPHIN TO COS-7 CELLS, MYOBLASTS, AND 
MYOTUBES 
Duchenne muscular dystrophy is an X-linked recessive neuromuscular disease caused by deficiency in the 
protein dystrophin, a key member of the dystrophin-associated protein complex in the sarcolemma. 
Dystrophin binds to and links the transmembrane protein β-dystroglycan with the actin cytoskeleton in 
skeletal muscle. In the absence of dystrophin, muscle cells undergo repeated cycles of regeneration and 
atrophy. Multiple studies have demonstrated that restoration of dystrophin to skeletal muscle via 
transgene expression or viral-mediated gene therapy ameliorates the disease phenotype[29]. However, 
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safe and efficient means to deliver the dystrophin gene to dystrophin-deficient muscle in a clinical setting 
have not yet materialized.  
The Fv fragment was tested as a means to deliver dystrophin protein directly to muscle cells, 
circumventing the need for gene therapy. Because full-length dystrophin is a large protein, 427 kDa in 
size, a microdystrophin protein was selected for fusion to the Fv fragment. Microdystrophin is a truncated 
version of the dystrophin protein that has been shown sufficient to prevent the dystrophic phenotype[30]. 
An Fv-microdystrophin (Fv-MD) fusion protein produced as an intracellular protein in P. pastoris was 
tested on L6 myoblasts and myotubes and Cos-7 cells. Fv-MD penetrated into the L6 cells and localized 
throughout the cytoplasm and nuclei, indicating that Fv is capable of delivering proteins to muscle 
cells[31]. 
More interestingly, Fv-MD was observed to penetrate into and localize to the periphery of Cos-7 
cells, apparently interacting with the cell membrane. Full-length, wild type dystrophin expressed as a 
transgene in Cos-7 cells also localized to the membrane of Cos-7 cells[32]. It is proposed that, similar to 
its behavior in muscle cells, dystrophin interacts with β-dystroglycan in the membrane of the Cos-7 cell, 
causing it to localize to the membrane. Staining for the presence of β-dystroglycan in the Cos-7 cells and 
the L6 cells used to test the Fv-MD revealed that only the Cos-7 cells possessed β-dystroglycan in their 
membranes. The immature L6 cells were found to have β-dystroglycan localized in a primarily 
perinuclear pattern. This difference in distribution of β-dystroglycan not only explains the different 
localization of Fv-MD in Cos-7 cells vs. L6 cells, but also suggests that Fv-MD is capable of interacting 
with β-dystroglycan at the Cos-7 cell membrane and therefore possesses at least some biological 
activity[31]. Further experiments in vivo are needed to determine Fv-MD’s potential as a clinical therapy 
for Duchenne muscular dystrophy. 
CONCLUSION 
mAb 3E10 and its Fv fragment are unique among all other protein transduction domains. The documented 
nuclear localization of mAb 3E10 and Fv makes them ideal agents for intranuclear delivery of proteins 
such as transcription factors. In a scientific era in which manipulation of gene expression is becoming 
increasingly relevant both in vitro and in vivo, a benign intranuclear delivery vehicle is highly desirable. 
An increasing number of investigators have attempted to use the HIV-1 Tat CPP to deliver specific 
transcription factors to stem cells in the hopes of driving their differentiation in a specific direction, and it 
is likely that Fv, with its intrinsic tendency to localize to the nucleus, could be highly successful in 
accomplishing such a task[33,34]. 
In addition to delivering peptides and proteins to nuclei, it is also apparent from recent studies that Fv 
can deliver proteins to the cytoplasm. The precise mechanism by which Fv enters into cells and then 
localizes into the nuclei or cytoplasm is presently unknown. However, there is likely an interaction 
between Fv and the cargo protein it carries into the cell that ultimately determines localization of the 
fusion protein. The ability to deliver proteins both to the nucleus and the cytoplasm of a cell makes the Fv 
fragment a diverse delivery vehicle, ideal for delivering proteins that may have both nuclear and 
cytoplasmic roles. For example, efforts are underway to develop an Fv-Hsp70 fusion protein as a 
potential therapy for ischemic stroke and myocardial infarction. The Fv fragment could also be used to 
deliver impermeable intrabodies into living cells[35,36].  
The use of an antibody-derived protein transduction domain in protein therapy is a plausible 
alternative to gene therapy and the CPPs. Replacement of a protein to cells and tissues in an organism 
which has never before encountered the protein is likely to result in the generation of an immune response 
to a variety of antigens on the missing protein. It is possible that mAb 3E10 or its Fv fragment will induce 
immune tolerance to themselves and to any protein cargo they carry into cells. mAb 3E10 and its Fv 
fragment have been clearly established as an effective means of delivering functional proteins to living 
cells in vitro. If they should prove equally as effective in vivo, they will have a profound impact on the 
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clinical viability of protein therapy for diseases caused by deficiency in a single protein and will have 
significant applications in the regulation of nuclear processes. 
REFERENCES 
1. Deshayes, S., Morris, M.C., Divita, G., and Heitz, F. (2005) Cell-penetrating peptides: tools for intracellular delivery 
of therapeutics. Cell. Mol. Life Sci. June 17. [Epub ahead of print]. 
2. Wadia, J.S. and Dowdy, S.F. (2005) Transmembrane delivery of protein and peptide drugs by TAT-mediated 
transduction in the treatment of cancer. Adv. Drug Deliv. Rev. 57(4), 579–596.  
3. Schwarze, S.R., Ho, A., Vocero-Akbani, A., and Dowdy, S.F. (1999) In vivo protein transduction: delivery of a 
biologically active protein into the mouse. Science 285(5433), 1569–1572. 
4. Kanovsky, M., Raffo, A., Drew, L., Rosal, R., Do, T., Friedman, F.K., Rubinstein, P., Visser, J., Robinson, R., 
Brandt-Rauf, P.W., Michl, J., Fine, R.L., and Pincus, M.R. (2001) Peptides from the amino terminal mdm-2-binding 
domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells. Proc. Natl. 
Acad. Sci. U. S. A. 98(22), 12438–12443. 
5. Phelan, A., Elliott, G., and O’Hare, P. (1998) Intercellular delivery of functional p53 by the herpesvirus protein VP22. 
Nat. Biotechnol. 16(5), 440–443. 
6. Matsui, H., Tomizawa, K., Lu, Y.F., and Matsushita, M. (2003) Protein therapy: in vivo protein transduction by 
polyarginine (11R) PTD and subcellular targeting delivery. Curr. Protein Pept. Sci. 4(2), 151–157. 
7. Toborek, M., Lee, Y.W., Pu, H., Malecki, A., Flora, G., Garrido, R., Hennig, B., Bauer, H.C., and Nath, A. (2003) 
HIV-Tat protein induces oxidative and inflammatory pathways in brain endothelium. J. Neurochem. 84(1), 169–179. 
8. Pu, H., Tian, J., Flora, G., Lee, Y.W., Nath, A., Hennig, B., and Toborek, M. (2003) HIV-1 Tat protein upregulates 
inflammatory mediators and induces monocyte invasion into the brain. Mol. Cell. Neurosci. 24(1), 224–237.  
9. Moulton, H.M., Hase, M.C., Smith, K.M., and Iversen, P.L. (2003) HIV Tat peptide enhances cellular delivery of 
antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev. 13(1), 31–43. 
10. Lai, Y., Du, L., Dunsmore, K.E., Jenkins, L.W., Wong, H.R., and Clark, R.S. (2005) Selectively increasing inducible 
heat shock protein 70 via TAT-protein transduction protects neurons from nitrosative stress and excitotoxicity. J. 
Neurochem. 94(2), 360–366.  
11. Gust, T.C. and Zenke, M. (2002) Receptor-mediated gene delivery. TheScientificWorldJOURNAL 2, 224–229. 
12. Alarcon-Segovia, D., Ruiz-Arguelles, A., and Fishbein, E. (1979) Antibody penetration into living cells. I. 
Intranuclear immunoglobulin in peripheral blood mononuclear cells in mixed connective tissue disease and systemic 
lupus erythematosus. Clin. Exp. Immunol. 35(3), 364–375. 
13. Okudaira, K., Yoshizawa, H., and Williams, Jr., R.C. (1987) Monoclonal murine anti-DNA antibody interacts with 
living mononuclear cells. Arthritis Rheum. 30(6), 669–678. 
14. Agarwal, R.K., Kang, Y., Zambidis, E., Scott, D.W., Chan, C.C., and Caspi, R.R. (2000) Retroviral gene therapy with 
an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis. J. Clin. Invest. 106(2), 
245–252. 
15. El-Amine, M., Melo, M., Kang, Y., Nguyen, H., Oian, J., and Scott, D.W. (2000) Mechanisms of tolerance induction 
by a gene-transferred peptide-IgG fusion protein expressed in B lineage cells. J. Immunol. 165(10), 5631–5636. 
16. Zack, D.J., Stempniak, M., Wong, A.L., Taylor, C., and Weisbart, R.H. (1996) Mechanisms of cellular penetration 
and nuclear localization of an anti-double strand DNA autoantibody. J. Immunol. 157(5), 2082–2088. 
17. Weisbart, R.H., Baldwin, R., Huh, B., Zack, D.J., and Nishimura, R. (2000) Novel protein transfection of primary rat 
cortical neurons using an antibody that penetrates living cells. J. Immunol. 164(11), 6020–6026. 
18. Weisbart, R.H., Stempniak, M., Harris, S., Zack, D.J., and Ferreri, K. (1998) An autoantibody is modified for use as a 
delivery system to target the cell nucleus: therapeutic implications. J. Autoimmun. 11(5), 539–546. 
19. Vousden, K.H. (2000) p53: death star. Cell 103, 691–694. 
20. Somasundaram, K. (2000) Tumor suppressor p53: regulation and function. Front. Biosci. 5, D424–D437. 
21. Blagosklonny, M.V. (2002) p53: an ubiquitous target of anticancer drugs. Int. J. Cancer 98(2), 161–166. 
 787
Hansen et al.: Antibody-mediated protein transduction TheScientificWorldJOURNAL (2005) 5, 782–788
 
 
22. Kim, A.L., Raffo, A.J., Brandt-Rauf, P.W., Pincus, M.R., Monaco, R., Abarzua, P., and Fine, R.L. (1999) 
Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells. J. 
Biol. Chem. 274(49), 34924–34931. 
23. Hupp, T.R., Meek, D.W., Midgley, C.A., and Lane, D.P. (1992) Regulation of the specific DNA binding function of 
p53. Cell 71, 875–886. 
24. Weisbart, R.H., Miller, C.W., Chan, G., Wakelin, R., Ferreri, K., and Koeffler, H.P. (2003) Nuclear delivery of p53 
C-terminal peptides into cancer cells using scFv fragments of a monoclonal antibody that penetrates living cells. 
Cancer Lett. 195(2), 211–219. 
25. Caron de Fromentel, C.C., Gruel, N., Venot, C., Debussche, L., Conseiller, E., Dureuil, C., Teillaud, J.L., Tocque, B., 
and Bracco, L. (1999) Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular 
expression of anti-p53 single chain Fv fragments. Oncogene 18, 551–557. 
26. Abarzu, P., LoSardo, J.E., Gubler, M.L., and Neri, A. (1995) Microinjection of monoclonal antibody PAb421 into 
human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53. Cancer Res. 55, 
3490–3494. 
27. Weisbart, R.H., Wakelin, R., Chan, G., Miller, C.W., and Koeffler, P.H. (2004) Construction and expression of a 
bispecific single-chain antibody that penetrates mutant p53 colon cancer cells and binds p53. Int. J. Oncol. 25(4), 
1113–1118. 
28. Weisbart, R.H., Hansen, J.E., Chan, G., Wakelin, R., Chang, S.S., Heinze, E., Miller, C.W., Koeffler, P.H., Yang, F., 
Cole, G.M., Min, Y.S., and Nishimura, R.N. (2004) Antibody-mediated transduction of p53 selectively kills cancer 
cells. Int. J. Oncol. 25(6), 1867–1873. 
29. Nowak, K.J. and Davies, K.E. (2004) Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities 
for treatment. EMBO Rep. 5(9), 872–876. 
30. Harper, S.Q., Hauser, M.A., DelloRusso, C., Duan, D., Crawford, R.W., Phelps, S.F., Harper, H.A., Robinson, A.S., 
Engelhardt, J.F., Brooks, S.V., and Chamberlain, J.S. (2002) Modular flexibility of dystrophin: implications for gene 
therapy of Duchenne muscular dystrophy. Nat. Med. 8(3), 253–261. 
31. Weisbart, R.H., Hansen, J.E., Nishimura, R.N., Chan, G., Wakelin, R., Chang, S.S., Baresi, L., and Chamberlain, J.S. 
(2005) An intracellular delivery vehicle for protein transduction of micro-dystrophin. J. Drug Target. 13(2), 81–87. 
32. Lee, C.C., Pearlman, J.A., Chamberlain, J.S., and Caskey, C.T. (1991) Expression of recombinant dystrophin and its 
localization to the cell membrane. Nature 349(6307), 334–336. 
33. Kwon, Y.D., Oh, S.K., Kim, H.S., Ku, S.Y., Kim, S.H., Choi, Y.M., and Moon, S.Y. (2005) Cellular manipulation of 
human embryonic stem cells by TAT-PDX1 protein transduction. Mol. Ther. 12(1), 28–32. 
34. Dominguez-Bendala, J., Klein, D., Ribeiro, M., Ricordi, C., Inverardi, L., Pastori, R., and Edlund, H. (2005) TAT-
mediated neurogenin 3 protein transduction stimulates pancreatic endocrine differentiation in vitro. Diabetes 54(3), 
720–726. 
35. Lobato, M.N. and Rabbitts, T.H. (2004) Intracellular antibodies as specific reagents for functional ablation: future 
therapeutic molecules. Curr. Mol. Med. 4(5), 519–528.  
36. Heng, B.C. and Cao, T. (2005) Making cell-permeable antibodies (Transbody) through fusion of protein transduction 
domains (PTD) with single chain variable fragment (scFv) antibodies: potential advantages over antibodies expressed 
within the intracellular environment (Intrabody). Med. Hypotheses 64(6), 1105–1108. 
 
 
 
This article should be referenced as follows: 
Hansen, J.E., Weisbart, R.H., and Nishimura, R.N. (2005) Antibody-mediated transduction of therapeutic proteins into living 
cells. TheScientificWorldJOURNAL 5, 782–788.  
Handling Editor: 
Ernst Wagner, Principal Editor for Gene, Molecular and Cell Therapy — a domain of TheScientificWorldJOURNAL. 
 
 
 788
